Robust implementation of liquid biopsy as a clinical tool in the management of EGFR resistant lung cancer warrants further harmonization of the diverse ctDNA analysis technologies and different platforms, and requires multicentric randomized controlled trials with larger cohorts of patients and controls [253]. The gene discussed is EGFR; the disease is lung carcinoma.